MYC and breast carcinoma: The MYC oncogene is a frequently amplified in human cancer and a recent synthetic lethal shRNA screen identified SAE1 and SAE2 (the two heterodimer components of the SUMO E1) as top hits that confer synthetic lethality in breast cancer cells with high MYC activity [18].